150 related articles for article (PubMed ID: 33035545)
41. Solid lipid nanoparticles as carriers for oral delivery of hydroxysafflor yellow A.
Zhao B; Gu S; Du Y; Shen M; Liu X; Shen Y
Int J Pharm; 2018 Jan; 535(1-2):164-171. PubMed ID: 29107614
[TBL] [Abstract][Full Text] [Related]
42. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2406-17. PubMed ID: 21491451
[TBL] [Abstract][Full Text] [Related]
43. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
[TBL] [Abstract][Full Text] [Related]
44. Solid lipid nanoparticles loaded with lipoyl-memantine codrug: preparation and characterization.
Laserra S; Basit A; Sozio P; Marinelli L; Fornasari E; Cacciatore I; Ciulla M; Türkez H; Geyikoglu F; Di Stefano A
Int J Pharm; 2015 May; 485(1-2):183-91. PubMed ID: 25747452
[TBL] [Abstract][Full Text] [Related]
45. Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
Zou Z; He D; He X; Wang K; Yang X; Qing Z; Zhou Q
Langmuir; 2013 Oct; 29(41):12804-10. PubMed ID: 24073830
[TBL] [Abstract][Full Text] [Related]
46. Ellagic acid encapsulated chitosan nanoparticles for drug delivery system in human oral cancer cell line (KB).
Arulmozhi V; Pandian K; Mirunalini S
Colloids Surf B Biointerfaces; 2013 Oct; 110():313-20. PubMed ID: 23732810
[TBL] [Abstract][Full Text] [Related]
47. Systematic Development of Sertraline Loaded Solid Lipid Nanoparticle (SLN) by Emulsification-Ultrasonication Method and Pharmacokinetic Study in Sprague-Dawley Rats.
Rahman MA; Harwansh RK; Iqbal Z
Pharm Nanotechnol; 2019; 7(2):162-176. PubMed ID: 30919786
[TBL] [Abstract][Full Text] [Related]
48. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
Dudhipala N; Janga KY; Gorre T
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
[TBL] [Abstract][Full Text] [Related]
49. Formulation, characterization and pharmacokinetics of Morin hydrate niosomes prepared from various non-ionic surfactants.
Waddad AY; Abbad S; Yu F; Munyendo WL; Wang J; Lv H; Zhou J
Int J Pharm; 2013 Nov; 456(2):446-58. PubMed ID: 23998955
[TBL] [Abstract][Full Text] [Related]
50. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan.
Rajpoot P; Bali V; Pathak K
Int J Pharm; 2012 Apr; 426(1-2):219-230. PubMed ID: 22301424
[TBL] [Abstract][Full Text] [Related]
51. Novel water-soluble fisetin/cyclodextrins inclusion complexes: Preparation, characterization, molecular docking and bioavailability.
Zhang JQ; Jiang KM; An K; Ren SH; Xie XG; Jin Y; Lin J
Carbohydr Res; 2015 Dec; 418():20-28. PubMed ID: 26531135
[TBL] [Abstract][Full Text] [Related]
52. A combination of complexation and self-nanoemulsifying drug delivery system for enhancing oral bioavailability and anticancer efficacy of curcumin.
Shukla M; Jaiswal S; Sharma A; Srivastava PK; Arya A; Dwivedi AK; Lal J
Drug Dev Ind Pharm; 2017 May; 43(5):847-861. PubMed ID: 27648633
[TBL] [Abstract][Full Text] [Related]
53. Enhanced oral bioavailability of morin administered in mixed micelle formulation with PluronicF127 and Tween80 in rats.
Choi YA; Yoon YH; Choi K; Kwon M; Goo SH; Cha JS; Choi MK; Lee HS; Song IS
Biol Pharm Bull; 2015; 38(2):208-17. PubMed ID: 25747979
[TBL] [Abstract][Full Text] [Related]
54. A solid lipid nanoparticle formulation of 4-(N)-docosahexaenoyl 2', 2'-difluorodeoxycytidine with increased solubility, stability, and antitumor activity.
Valdes SA; Alzhrani RF; Rodriguez A; Lansakara-P DSP; Thakkar SG; Cui Z
Int J Pharm; 2019 Oct; 570():118609. PubMed ID: 31415878
[TBL] [Abstract][Full Text] [Related]
55. Aloe-emodin loaded solid lipid nanoparticles: formulation design and in vitro anti-cancer study.
Chen R; Wang S; Zhang J; Chen M; Wang Y
Drug Deliv; 2015; 22(5):666-74. PubMed ID: 24512431
[TBL] [Abstract][Full Text] [Related]
56. Alpha-lipoic acid-stearylamine conjugate-based solid lipid nanoparticles for tamoxifen delivery: formulation, optimization, in-vivo pharmacokinetic and hepatotoxicity study.
Dhaundiyal A; Jena SK; Samal SK; Sonvane B; Chand M; Sangamwar AT
J Pharm Pharmacol; 2016 Dec; 68(12):1535-1550. PubMed ID: 27709612
[TBL] [Abstract][Full Text] [Related]
57. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma.
Saha S; Yakati V; Shankar G; Jaggarapu MMCS; Moku G; Madhusudana K; Banerjee R; Ramkrishna S; Srinivas R; Chaudhuri A
J Mater Chem B; 2020 May; 8(19):4318-4330. PubMed ID: 32330214
[TBL] [Abstract][Full Text] [Related]
58. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2366-78. PubMed ID: 21491449
[TBL] [Abstract][Full Text] [Related]
59. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of curcumin.
Ji H; Tang J; Li M; Ren J; Zheng N; Wu L
Drug Deliv; 2016; 23(2):459-70. PubMed ID: 24892628
[TBL] [Abstract][Full Text] [Related]
60. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics.
Kumar VV; Chandrasekar D; Ramakrishna S; Kishan V; Rao YM; Diwan PV
Int J Pharm; 2007 Apr; 335(1-2):167-175. PubMed ID: 17161566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
